Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.5920
Samuel J F Melville, Jeanne Shi, Bharti Garg, Aaron B Caughey, Molly Kornfield
Importance: Twenty-seven states have enacted targeted regulation of abortion providers (TRAP) laws that may disproportionately affect higher-risk pregnancies such as those conceived through fertility treatment.
Objective: To assess the association of TRAP laws with the relative rates of adverse outcomes of pregnancies conceived through fertility treatment.
Design, setting, and participants: This cohort study of singleton births conceived through fertility treatment used National Vital Statistics System data on births between 2012 and 2021. Data were analyzed from August 15, 2024, to September 8, 2025.
Exposure: Included participants were categorized as either living under the legal jurisdiction of states with or without TRAP laws enacted during the study period. As laws were not passed in every state uniformly, the first year of enforcement was excluded.
Main outcomes and measures: Demographic characteristics of individuals who conceived with fertility treatments living in states with and without TRAP laws were compared using χ2 and analysis of variance tests. A maternal composite of adverse outcomes was constructed. Secondary outcomes included a neonatal composite of adverse outcomes and rate of preterm birth. Controlling for potential confounders, generalized estimating equation models with binomial distribution, identity link, and robust sandwich SE estimators were used to assess adjusted absolute percentage point differences comparing states with and without TRAP laws across the enactment of TRAP laws.
Results: This study included 416 019 singleton births (mean [SD] maternal age, 34.5 [5.3] years; mean [SD] gestational age, 38.3 [2.4] weeks; 213 294 males [51.3%]) conceived with fertility treatment. Of these births, 174 671 (42.0%) occurred in states with TRAP laws and 241 348 (58.0%) in states without these laws. Generalized estimating equation models demonstrated a greater increase in the composite of adverse maternal outcomes (absolute adjusted difference-in-differences, 0.25; 95% CI, 0.003-0.50) in states with TRAP laws relative to states without.
Conclusions and relevance: These findings suggest an increase in maternal morbidity among patients using fertility care in states that passed TRAP laws relative to states that did not.
{"title":"Targeted Regulation of Abortion Providers Laws and Pregnancies Conceived Through Fertility Treatment.","authors":"Samuel J F Melville, Jeanne Shi, Bharti Garg, Aaron B Caughey, Molly Kornfield","doi":"10.1001/jamahealthforum.2025.5920","DOIUrl":"10.1001/jamahealthforum.2025.5920","url":null,"abstract":"<p><strong>Importance: </strong>Twenty-seven states have enacted targeted regulation of abortion providers (TRAP) laws that may disproportionately affect higher-risk pregnancies such as those conceived through fertility treatment.</p><p><strong>Objective: </strong>To assess the association of TRAP laws with the relative rates of adverse outcomes of pregnancies conceived through fertility treatment.</p><p><strong>Design, setting, and participants: </strong>This cohort study of singleton births conceived through fertility treatment used National Vital Statistics System data on births between 2012 and 2021. Data were analyzed from August 15, 2024, to September 8, 2025.</p><p><strong>Exposure: </strong>Included participants were categorized as either living under the legal jurisdiction of states with or without TRAP laws enacted during the study period. As laws were not passed in every state uniformly, the first year of enforcement was excluded.</p><p><strong>Main outcomes and measures: </strong>Demographic characteristics of individuals who conceived with fertility treatments living in states with and without TRAP laws were compared using χ2 and analysis of variance tests. A maternal composite of adverse outcomes was constructed. Secondary outcomes included a neonatal composite of adverse outcomes and rate of preterm birth. Controlling for potential confounders, generalized estimating equation models with binomial distribution, identity link, and robust sandwich SE estimators were used to assess adjusted absolute percentage point differences comparing states with and without TRAP laws across the enactment of TRAP laws.</p><p><strong>Results: </strong>This study included 416 019 singleton births (mean [SD] maternal age, 34.5 [5.3] years; mean [SD] gestational age, 38.3 [2.4] weeks; 213 294 males [51.3%]) conceived with fertility treatment. Of these births, 174 671 (42.0%) occurred in states with TRAP laws and 241 348 (58.0%) in states without these laws. Generalized estimating equation models demonstrated a greater increase in the composite of adverse maternal outcomes (absolute adjusted difference-in-differences, 0.25; 95% CI, 0.003-0.50) in states with TRAP laws relative to states without.</p><p><strong>Conclusions and relevance: </strong>These findings suggest an increase in maternal morbidity among patients using fertility care in states that passed TRAP laws relative to states that did not.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e255920"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.5890
Benjamin N Rome, Jihye Han, Adrianna McIntyre, Aaron S Kesselheim, Benjamin D Sommers
<p><strong>Importance: </strong>During the COVID-19 pandemic, Medicaid enrollment increased because states suspended routine eligibility determinations. After this continuous enrollment provision ended in April 2023, millions of US individuals lost Medicaid coverage.</p><p><strong>Objective: </strong>To measure how the unwinding of Medicaid enrollment was associated with changes in patients' use of health services, such as prescription medications.</p><p><strong>Design, setting, and participants: </strong>A cross-sectional study was carried out using interrupted time series analysis to compare changes in quarterly Medicaid enrollment and prescription medication use from 2018, quarter (Q) 1 through 2024, Q1. Data were analyzed from November 2024 to February 2025.</p><p><strong>Exposures: </strong>The onset of continuous enrollment provision (2020, Q2) and unwinding (2023, Q2).</p><p><strong>Main outcomes and measures: </strong>The outcomes were quarterly state Medicaid enrollment and estimated number of reimbursed prescriptions. Log-transformed linear regression models were used to compare changes in state enrollment and prescriptions after continuous enrollment and unwinding, overall and stratified by states with different net enrollment changes and policies to protect patients during unwinding. Subsets of medications for certain chronic conditions and formulations primarily used by children were analyzed.</p><p><strong>Results: </strong>In the quarter before the COVID-19 pandemic (2019, Q4), Medicaid enrollment was 71.4 million, and there were about 183.2 million prescriptions reimbursed by Medicaid programs. This included 59.1 million (32.3%) prescriptions treating chronic diseases, 30.3 million (16.5%) for acute conditions, and 15.0 million (8.2%) for other specified conditions. In 2023, Q2, enrollment peaked at 93.9 million (31.4% increase from baseline), and the number of prescriptions peaked at 212.6 million (16.1% increase from baseline). Enrollment increased by 2.42% (95% CI, 2.15%-2.70%) per quarter during continuous enrollment and decreased by 4.92% (95% CI, -6.12% to -3.70%) per quarter during unwinding. Concurrently, the number of prescriptions increased by 1.85% (95% CI, 1.21%-2.50%) per quarter and then decreased by 3.94% (95% CI, -5.73% to -2.11%) per quarter. Trends were similar for chronic disease medications and pediatric-specific formulations. States with the highest disenrollment during unwinding had the largest decreases in chronic disease medication use; states that implemented more protective policies had smaller decreases in enrollment and insignificant decreases in chronic medication use.</p><p><strong>Conclusions and relevance: </strong>This cross-sectional study found that changes in Medicaid medication use during the COVID-19 pandemic continuous enrollment period and after unwinding were smaller than corresponding changes in enrollment. Unwinding had measurable impacts on patient access to prescription medications, but
{"title":"Changes in Medication Use During Medicaid Continuous Enrollment and Unwinding.","authors":"Benjamin N Rome, Jihye Han, Adrianna McIntyre, Aaron S Kesselheim, Benjamin D Sommers","doi":"10.1001/jamahealthforum.2025.5890","DOIUrl":"10.1001/jamahealthforum.2025.5890","url":null,"abstract":"<p><strong>Importance: </strong>During the COVID-19 pandemic, Medicaid enrollment increased because states suspended routine eligibility determinations. After this continuous enrollment provision ended in April 2023, millions of US individuals lost Medicaid coverage.</p><p><strong>Objective: </strong>To measure how the unwinding of Medicaid enrollment was associated with changes in patients' use of health services, such as prescription medications.</p><p><strong>Design, setting, and participants: </strong>A cross-sectional study was carried out using interrupted time series analysis to compare changes in quarterly Medicaid enrollment and prescription medication use from 2018, quarter (Q) 1 through 2024, Q1. Data were analyzed from November 2024 to February 2025.</p><p><strong>Exposures: </strong>The onset of continuous enrollment provision (2020, Q2) and unwinding (2023, Q2).</p><p><strong>Main outcomes and measures: </strong>The outcomes were quarterly state Medicaid enrollment and estimated number of reimbursed prescriptions. Log-transformed linear regression models were used to compare changes in state enrollment and prescriptions after continuous enrollment and unwinding, overall and stratified by states with different net enrollment changes and policies to protect patients during unwinding. Subsets of medications for certain chronic conditions and formulations primarily used by children were analyzed.</p><p><strong>Results: </strong>In the quarter before the COVID-19 pandemic (2019, Q4), Medicaid enrollment was 71.4 million, and there were about 183.2 million prescriptions reimbursed by Medicaid programs. This included 59.1 million (32.3%) prescriptions treating chronic diseases, 30.3 million (16.5%) for acute conditions, and 15.0 million (8.2%) for other specified conditions. In 2023, Q2, enrollment peaked at 93.9 million (31.4% increase from baseline), and the number of prescriptions peaked at 212.6 million (16.1% increase from baseline). Enrollment increased by 2.42% (95% CI, 2.15%-2.70%) per quarter during continuous enrollment and decreased by 4.92% (95% CI, -6.12% to -3.70%) per quarter during unwinding. Concurrently, the number of prescriptions increased by 1.85% (95% CI, 1.21%-2.50%) per quarter and then decreased by 3.94% (95% CI, -5.73% to -2.11%) per quarter. Trends were similar for chronic disease medications and pediatric-specific formulations. States with the highest disenrollment during unwinding had the largest decreases in chronic disease medication use; states that implemented more protective policies had smaller decreases in enrollment and insignificant decreases in chronic medication use.</p><p><strong>Conclusions and relevance: </strong>This cross-sectional study found that changes in Medicaid medication use during the COVID-19 pandemic continuous enrollment period and after unwinding were smaller than corresponding changes in enrollment. Unwinding had measurable impacts on patient access to prescription medications, but","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e255890"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12761332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6294
Yanlei Ma, Eric T Roberts, Jessica Phelan, Kenton J Johnston, E John Orav, Ellen R Meara, Jose F Figueroa
<p><strong>Importance: </strong>In 2023, the Centers for Medicare & Medicaid Services terminated dual-eligible special needs plan look-alikes-Medicare Advantage plans with beneficiary panels composed of more than 80% dual-eligible individuals but lacking Medicaid integration. Understanding whether this policy promoted dual-eligible enrollment in integrated care plans, particularly those attaining high-level integration, is critical.</p><p><strong>Objective: </strong>To describe dual-eligible enrollment transitions after the look-alike plan termination and evaluate whether the policy was associated with increased enrollment in highly integrated plans.</p><p><strong>Design, setting, and participants: </strong>This repeated cross-sectional study analyzed US Medicare administrative data from January 2017 to January 2023. Samples were limited to full-benefit dual-eligible beneficiaries.</p><p><strong>Main outcomes and measures: </strong>First, a beneficiary-level analysis was conducted on 2023 enrollment patterns among full-benefit dual-eligible individuals whose 2022 plans were terminated, including factors associated with enrollment in highly integrated plans in 2023. Next, a county-year-level difference-in-differences design was used to compare changes in full-benefit dual-eligible enrollment before (2017-2022) and after (2023) the termination policy between counties with vs without terminated look-alike plans. A difference-in-differences design was used to evaluate whether the look-alike termination policy was associated with the proportion of full-benefit dual-eligible individuals enrolled in highly integrated care plans.</p><p><strong>Results: </strong>Between 2017 and 2022, 482 of 2576 counties had full-benefit dual-eligible individuals enrolled in look-alike plans for at least 1 year. Of the 170 399 full-benefit dual-eligible individuals enrolled in look-alike plans in 2022 (58.9% female; 20.6% Asian, 44.8% Hispanic, 11.3% non-Hispanic Black, 21.4% non-Hispanic White, and 2% other) and remained dual-eligible in 2023, only 5.4% transitioned to highly integrated plans, while 55.6% moved to nonintegrated plans. Dual-eligible individuals transitioning to highly integrated plans were more likely to be older (65-74 years: adjusted difference, 3.4 percentage points [pp]; 95% CI, 2.8-4.1 pp; 75-84 years: adjusted difference, 4.1 pp; 95% CI, 3.3-4.8 pp; ≥85 years: adjusted difference, 5.0 pp; 95% CI, 4.0-5.9 pp), female (adjusted difference: 0.6 pp; 95% CI, 0.2-0.9 pp), without disabilities (adjusted difference, -0.7 pp; 95% CI, -1.2 to -0.2 pp), and less likely to be Asian (adjusted difference, -5.0 pp; 95% CI, -5.6 to -4.4 pp) or Black (adjusted difference, -0.9 pp; 95% CI, -1.6 to -0.2 pp). The termination policy was not associated with a significant differential increase in enrollment into highly integrated plans in counties with look-alike plans compared with those without (0.6 pp; 95% CI, -0.4 to 1.6 pp). However, there was a 2.6-pp differential
{"title":"Federal Look-Alike Plan Termination Policy and Dual-Eligible Enrollment in Integrated Care Programs.","authors":"Yanlei Ma, Eric T Roberts, Jessica Phelan, Kenton J Johnston, E John Orav, Ellen R Meara, Jose F Figueroa","doi":"10.1001/jamahealthforum.2025.6294","DOIUrl":"10.1001/jamahealthforum.2025.6294","url":null,"abstract":"<p><strong>Importance: </strong>In 2023, the Centers for Medicare & Medicaid Services terminated dual-eligible special needs plan look-alikes-Medicare Advantage plans with beneficiary panels composed of more than 80% dual-eligible individuals but lacking Medicaid integration. Understanding whether this policy promoted dual-eligible enrollment in integrated care plans, particularly those attaining high-level integration, is critical.</p><p><strong>Objective: </strong>To describe dual-eligible enrollment transitions after the look-alike plan termination and evaluate whether the policy was associated with increased enrollment in highly integrated plans.</p><p><strong>Design, setting, and participants: </strong>This repeated cross-sectional study analyzed US Medicare administrative data from January 2017 to January 2023. Samples were limited to full-benefit dual-eligible beneficiaries.</p><p><strong>Main outcomes and measures: </strong>First, a beneficiary-level analysis was conducted on 2023 enrollment patterns among full-benefit dual-eligible individuals whose 2022 plans were terminated, including factors associated with enrollment in highly integrated plans in 2023. Next, a county-year-level difference-in-differences design was used to compare changes in full-benefit dual-eligible enrollment before (2017-2022) and after (2023) the termination policy between counties with vs without terminated look-alike plans. A difference-in-differences design was used to evaluate whether the look-alike termination policy was associated with the proportion of full-benefit dual-eligible individuals enrolled in highly integrated care plans.</p><p><strong>Results: </strong>Between 2017 and 2022, 482 of 2576 counties had full-benefit dual-eligible individuals enrolled in look-alike plans for at least 1 year. Of the 170 399 full-benefit dual-eligible individuals enrolled in look-alike plans in 2022 (58.9% female; 20.6% Asian, 44.8% Hispanic, 11.3% non-Hispanic Black, 21.4% non-Hispanic White, and 2% other) and remained dual-eligible in 2023, only 5.4% transitioned to highly integrated plans, while 55.6% moved to nonintegrated plans. Dual-eligible individuals transitioning to highly integrated plans were more likely to be older (65-74 years: adjusted difference, 3.4 percentage points [pp]; 95% CI, 2.8-4.1 pp; 75-84 years: adjusted difference, 4.1 pp; 95% CI, 3.3-4.8 pp; ≥85 years: adjusted difference, 5.0 pp; 95% CI, 4.0-5.9 pp), female (adjusted difference: 0.6 pp; 95% CI, 0.2-0.9 pp), without disabilities (adjusted difference, -0.7 pp; 95% CI, -1.2 to -0.2 pp), and less likely to be Asian (adjusted difference, -5.0 pp; 95% CI, -5.6 to -4.4 pp) or Black (adjusted difference, -0.9 pp; 95% CI, -1.6 to -0.2 pp). The termination policy was not associated with a significant differential increase in enrollment into highly integrated plans in counties with look-alike plans compared with those without (0.6 pp; 95% CI, -0.4 to 1.6 pp). However, there was a 2.6-pp differential ","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256294"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6433
Louis P Garrison, Bruce C M Wang
{"title":"Stakeholder Engagement for Hepatitis C Virus Elimination.","authors":"Louis P Garrison, Bruce C M Wang","doi":"10.1001/jamahealthforum.2025.6433","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6433","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256433"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6261
Jessica I Billig, Joseph H Joo, Jennifer R Cardin, Michael D Dang, Ching-Ching Claire Lin, Jim P Stimpson, Joshua M Liao
{"title":"Early Adoption of Services for Health-Related Social Needs in Medicare.","authors":"Jessica I Billig, Joseph H Joo, Jennifer R Cardin, Michael D Dang, Ching-Ching Claire Lin, Jim P Stimpson, Joshua M Liao","doi":"10.1001/jamahealthforum.2025.6261","DOIUrl":"10.1001/jamahealthforum.2025.6261","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256261"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6031
Yiran Wang, Alicia E Boyd, Lillian Rountree, Yi Ren, Kate Nyhan, Ruchit Nagar, Jackson Higginbottom, Megan L Ranney, Harsh Parikh, Bhramar Mukherjee
Importance: Public health decisions increasingly rely on large-scale data and emerging technologies such as artificial intelligence and mobile health. However, many populations-including those in rural areas, with disabilities, experiencing homelessness, or living in low- and middle-income regions of the world-remain underrepresented in health datasets, leading to biased findings and suboptimal health outcomes for certain subgroups. Addressing data inequities is critical to ensuring that technological and digital advances improve health outcomes for all.
Observations: This article proposes 10 core concepts to improve data equity throughout the operational arc of data science research and practice in public health. The framework integrates computer science principles such as fairness, transparency, and privacy protection, with best practices in public health data science that focus on mitigating information and selection biases, learning causality, and ensuring generalizability. These concepts are applied together throughout the data life cycle, from study design to data collection, analysis, and interpretation to policy translation, offering a structured approach for evaluating whether data practices adequately represent and serve all populations.
Conclusions and relevance: Data equity is a foundational requirement for producing trustworthy inference and actionable evidence. When data equity is built into public health research from the start, technological and digital advances are more likely to improve health outcomes for everyone rather than widening existing health gaps. These 10 core concepts can be used to operationalize data equity in public health. Although data equity is an essential first step, it does not automatically guarantee information, learning, or decision equity. Advancing data equity must be accompanied by parallel efforts in information theory and structural changes that promote informed decision-making.
{"title":"Ten Core Concepts for Ensuring Data Equity in Public Health.","authors":"Yiran Wang, Alicia E Boyd, Lillian Rountree, Yi Ren, Kate Nyhan, Ruchit Nagar, Jackson Higginbottom, Megan L Ranney, Harsh Parikh, Bhramar Mukherjee","doi":"10.1001/jamahealthforum.2025.6031","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6031","url":null,"abstract":"<p><strong>Importance: </strong>Public health decisions increasingly rely on large-scale data and emerging technologies such as artificial intelligence and mobile health. However, many populations-including those in rural areas, with disabilities, experiencing homelessness, or living in low- and middle-income regions of the world-remain underrepresented in health datasets, leading to biased findings and suboptimal health outcomes for certain subgroups. Addressing data inequities is critical to ensuring that technological and digital advances improve health outcomes for all.</p><p><strong>Observations: </strong>This article proposes 10 core concepts to improve data equity throughout the operational arc of data science research and practice in public health. The framework integrates computer science principles such as fairness, transparency, and privacy protection, with best practices in public health data science that focus on mitigating information and selection biases, learning causality, and ensuring generalizability. These concepts are applied together throughout the data life cycle, from study design to data collection, analysis, and interpretation to policy translation, offering a structured approach for evaluating whether data practices adequately represent and serve all populations.</p><p><strong>Conclusions and relevance: </strong>Data equity is a foundational requirement for producing trustworthy inference and actionable evidence. When data equity is built into public health research from the start, technological and digital advances are more likely to improve health outcomes for everyone rather than widening existing health gaps. These 10 core concepts can be used to operationalize data equity in public health. Although data equity is an essential first step, it does not automatically guarantee information, learning, or decision equity. Advancing data equity must be accompanied by parallel efforts in information theory and structural changes that promote informed decision-making.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256031"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6576
Sugy Choi, Ninez A Ponce, Sandro Galea
{"title":"Advancing the Science and Scholarship of Health Equity.","authors":"Sugy Choi, Ninez A Ponce, Sandro Galea","doi":"10.1001/jamahealthforum.2025.6576","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6576","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256576"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6118
Yesne Alici, Liz Blackler, Julia Danielle Kulikowski, Amy Scharf
{"title":"Medical Aid in Dying and Our Ethical Duties-Call to Action.","authors":"Yesne Alici, Liz Blackler, Julia Danielle Kulikowski, Amy Scharf","doi":"10.1001/jamahealthforum.2025.6118","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6118","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256118"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6286
Alex Dahlen, Frederick Lei, Kofi Agyabeng, Runhan Chen, Christian E Johnson, Gabriel Amaro, Jake Spinnler, Mehrdad Khezri, José A Pagán, Cheryl Healton, Tilda M Farhat
Importance: The monthly opioid overdose death rate in the US has declined by 50% from its peak in the summer of 2023 through fall of 2024, and the factors associated with this decline are not fully understood.
Objective: To examine the association between the proportion of fentanyl reports in illicit drug seizures and opioid overdose deaths during periods of rising and falling mortality.
Design and setting: This secondary analysis of state-month level panel data from the National Forensic Laboratory Information System and US Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) was conducted from January 2018 to September 2024 and included all 50 US states and Washington, DC. CDC WONDER data were collected from recorded death certificates; National Forensic Laboratory Information System data were obtained from drug reports submitted by forensic laboratories. The data were analyzed from July to August 2025.
Exposure: Percentage of illicit drug seizures that contained fentanyl or fentanyl-related compounds. Illicit drug seizures were defined as seizures that contained any of the following: fentanyl or fentanyl-related compounds, heroin, methamphetamine, cocaine, and xylazine.
Main outcomes and measures: The monthly count of opioid overdose deaths, given by uniform claim descriptor codes X40 to 44, X60 to 64, X85, and Y10 to Y14, with additional multiple cause of death codes of T40.0 to 4 and T40.6. Death rates were calculated using yearly population estimates from the American Community Survey.
Results: From a peak in the summer of 2023 through the fall of 2024, the monthly opioid overdose death rate declined by 50%, from 2.2 to 1.1 per 100 000. This decline was was accompanied by a decline in the fentanyl reports as a proportion of total illicit drug seizures from 28.8% to 23.2%. In a 2-way, fixed-effects model, a 1-percentage point reduction in fentanyl prevalence was associated with 0.018 fewer overdose deaths per 100 000 population per month (95% CI, 0.016-0.019; P < .001). There was evidence that the strength of this association has decreased over time.
Conclusions and relevance: The study results suggest that current decline in the proportion of fentanyl reports in illicit drug seizures is associated with 9.2% of the total observed decline in mortality. Additional contributing factors may include other shifts in the drug supply not captured by fentanyl prevalence in illicit drug seizures, shifts in drug use behavior, and the effect of public health programs, interventions, and policies.
{"title":"Proportion of Fentanyl Reports in Illicit Drug Seizures and Opioid Mortality.","authors":"Alex Dahlen, Frederick Lei, Kofi Agyabeng, Runhan Chen, Christian E Johnson, Gabriel Amaro, Jake Spinnler, Mehrdad Khezri, José A Pagán, Cheryl Healton, Tilda M Farhat","doi":"10.1001/jamahealthforum.2025.6286","DOIUrl":"10.1001/jamahealthforum.2025.6286","url":null,"abstract":"<p><strong>Importance: </strong>The monthly opioid overdose death rate in the US has declined by 50% from its peak in the summer of 2023 through fall of 2024, and the factors associated with this decline are not fully understood.</p><p><strong>Objective: </strong>To examine the association between the proportion of fentanyl reports in illicit drug seizures and opioid overdose deaths during periods of rising and falling mortality.</p><p><strong>Design and setting: </strong>This secondary analysis of state-month level panel data from the National Forensic Laboratory Information System and US Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) was conducted from January 2018 to September 2024 and included all 50 US states and Washington, DC. CDC WONDER data were collected from recorded death certificates; National Forensic Laboratory Information System data were obtained from drug reports submitted by forensic laboratories. The data were analyzed from July to August 2025.</p><p><strong>Exposure: </strong>Percentage of illicit drug seizures that contained fentanyl or fentanyl-related compounds. Illicit drug seizures were defined as seizures that contained any of the following: fentanyl or fentanyl-related compounds, heroin, methamphetamine, cocaine, and xylazine.</p><p><strong>Main outcomes and measures: </strong>The monthly count of opioid overdose deaths, given by uniform claim descriptor codes X40 to 44, X60 to 64, X85, and Y10 to Y14, with additional multiple cause of death codes of T40.0 to 4 and T40.6. Death rates were calculated using yearly population estimates from the American Community Survey.</p><p><strong>Results: </strong>From a peak in the summer of 2023 through the fall of 2024, the monthly opioid overdose death rate declined by 50%, from 2.2 to 1.1 per 100 000. This decline was was accompanied by a decline in the fentanyl reports as a proportion of total illicit drug seizures from 28.8% to 23.2%. In a 2-way, fixed-effects model, a 1-percentage point reduction in fentanyl prevalence was associated with 0.018 fewer overdose deaths per 100 000 population per month (95% CI, 0.016-0.019; P < .001). There was evidence that the strength of this association has decreased over time.</p><p><strong>Conclusions and relevance: </strong>The study results suggest that current decline in the proportion of fentanyl reports in illicit drug seizures is associated with 9.2% of the total observed decline in mortality. Additional contributing factors may include other shifts in the drug supply not captured by fentanyl prevalence in illicit drug seizures, shifts in drug use behavior, and the effect of public health programs, interventions, and policies.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256286"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1001/jamahealthforum.2025.6049
Sandro Galea, Julie Donohue
{"title":"In Search of Pharmaceutical Policy Innovation in the US.","authors":"Sandro Galea, Julie Donohue","doi":"10.1001/jamahealthforum.2025.6049","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6049","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256049"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}